ACS Fall 2023 First Disclosures

The First Disclosures sessions at the 2023 ACS Fall Meeting in San Francisco, organized by Nikki Goodwin, presented a variety of new orally available small molecules. The standing room-only sessions were so highly attended that many attendees were unfortunately kicked out due to the fire code. In case you missed any of these exciting molecules, from Scorpion’s mutant-selective PI3Kα inhibitor to Nurix’s CNS-penetrant BTK degrader, here we share the structures and targets of all the novel molecules disclosed at the session.

Download the PDF of the newly disclosed small molecule therapeautics

The newly disclosed small molecule therapeutics included:

• TNG-462: An oral MTA-cooperative PRMT5 inhibitor (Tango Therapeutics)

• STC15: A first-in-class and first-in-clinic oral METTL3 inhibitor (Storm Therapeutics)

• STX-478: An oral CNS-penetrant allosteric mutant-selective PI3Kα inhibitor (Scorpion Therapeutics)

• JNT-517: An oral allosteric SLC6A19 inhibitor (Jnana Therapeutics)

• CHK-336: A first-in-class oral LDHA inhibitor (Chinook Therapeutics)

• GDC-6599: A first-in-class oral TRPA1 inhibitor (Genentech)

• KIN-3248: An oral covalent pan-FGFR inhibitor (Kinnate Biopharma)

• NX-5948: An oral CNS-penetrant BTK targeted degrader (Nurix Therapeutics)

• KT-474: An oral selective IRAK4 degrader (Kymera, Sanofi)

• RPT193: An oral CCR4 antagonist (RAPT Therapeutics)

• EDI048: A first-in-class oral soft-drug Cp PI(4)K inhibitor (Novartis)

• PF-07817883: A metabolically-stable SARS-CoV-2 Mpro inhibitor (Pfizer)

Our team will be covering each molecule in more depth in the coming days. Stay tuned!